Wednesday, October 22, 2025

4:55 PM - 5:40 PM

---

Details

Presentations continue... Presentation 12: Selective Small Molecule Inhibitors of Tau–LRP1 Binding as novel disease modifying therapeutics for Alzheimer’s and related tauopathies Presented by: Dr. Travis Stiles, CEO & CSO, Novoroo Bioscience Presentation 13: Beyond Dopamine: Targeting Neuroinflammation in Parkinson’s Disease - A First-in-Class oral C5aR1 Inhibitor Presented by: Dr. Adam Stephenson (2nd), Associate, Uniquest Pty Limited Presentation 14: Novel non-GLP-based therapeutic for improved treatment of metabolic disease Presented by: Dr. Christina Sparbier, Business Development Manager, The Florey